VF
NRIX icon

Virtu Financial’s Nurix Therapeutics NRIX Stock Holding History

Virtu Financial’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,256
Closed -$205K – 2040
2026
Q1 		$205K Buy
+13,256
New +$220K 0.01% 1015
2021
Q3 		– Sell
-7,574
Closed -$201K – 1816
2021
Q2 		$201K Buy
+7,574
New +$222K 0.02% 993

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Virtu Financial's NRIX Position: Q2 2026 in Review

Virtu Financial sold out of Nurix Therapeutics (NRIX) in Q2 2026, closing a stake of 13,256 shares — an estimated $205K sold.

Virtu Financial first reported a position in NRIX in Q2 2021 and held it in 2 quarters. The position peaked at $205K in Q1 2026. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Virtu Financial reported no remaining Nurix Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Virtu Financial sold 13,256 Nurix Therapeutics shares in Q2 2026, an estimated $205K.
  • Virtu Financial first reported a position in Nurix Therapeutics in Q2 2021 and held it in 2 quarters.
  • Virtu Financial's Nurix Therapeutics position peaked at $205K in Q1 2026.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.